Skip to content

What are the obstacles in utilization of golcadomide in DLBCL?
DOCK1 inhibition in TP53-mutant clonal hematopoiesis
EC approves tafasitamab combo in relapsed follicular lymphoma
What are the areas of unmet needs in large cell lymphoma?
What is the 2025 treatment landscape in DLBCL?

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Can radiation prime the immune system to fight blood cancer?

Cellular Therapy

Can radiation prime the immune system to fight blood cancer?

Leukemia

Can radiation prime the immune system to fight blood cancer?

Lymphoma

Can radiation prime the immune system to fight blood cancer?

Multiple Myeloma

Can radiation prime the immune system to fight blood cancer?

Myelodysplastic Syndromes

Can radiation prime the immune system to fight blood cancer?

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

December 22, 2025

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

SOHO Insider Hem/Onc Library Cellular Therapy

Cellular Therapy

Cellular Therapy Lymphoma Aggressive B-Cell Lymphomas Multiple Myeloma News

Can radiation prime the immune system to fight blood cancer?

by Leah Sherwood
August 1, 2025
0 Comments

Chimeric antigen receptor

Cellular Therapy Lymphoma

Armored CAR-T option shows promise in previously CAR-treated lymphoma

by SOHO Insider Editors
May 19, 2025
0 Comments

Cellular Therapy 2025 AACR Annual Meeting Multiple Myeloma

Trispecific therapy ISB 2001 active in ongoing early myeloma trial

by Leah Sherwood
April 29, 2025
0 Comments

Cellular therapy

Cellular Therapy

Early-phase study shows promise of novel CAR-T talicabtagene autoleucel for B-cell malignancies

by SOHO Insider Editors
April 11, 2025
0 Comments

Cellular Therapy Lymphoma News

Machine learning identifies inflammatory biomarker that predicts CAR-T response in lymphoma patients

by Leah Sherwood
April 3, 2025
0 Comments

Apheresis machine to extract plasma and platelet from whole blood

Cellular Therapy Lymphoma News

Risk factors for manufacturing failure, associated outcomes in patients receiving CAR-T for LBCL

by SOHO Insider Editors
March 18, 2025
0 Comments

Fried salmon steak with vegetables on wooden table

Cellular Therapy News

How do lifestyle factors play a role in the response to CAR-T therapy?

by Leah Sherwood
March 13, 2025
0 Comments

Chimeric antigen therapy

Cellular Therapy Multiple Myeloma

Patient case highlights secondary tumor after CAR-T treatment for myeloma

by SOHO Insider Editors
March 12, 2025
0 Comments

Megan Melody, MD

Cellular Therapy Lymphoma News Society Updates Young Investigator Program

SOHO Young Investigator Spotlight: Meet Megan Melody, MD

by Leah Sherwood
March 7, 2025
0 Comments

cancer cell

Cellular Therapy Lymphoma

CAR-NK cell therapy FT596 ‘well tolerated’ in phase 1 trial

by Leah Sherwood
January 16, 2025
0 Comments

1
2

Top Categories

Cellular Therapy

13

Leukemia

75

Lymphoma

73

Multiple Myeloma

65

Myelodysplastic Syndromes

24

Myeloproliferative Neoplasms

12

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

CAR-NK cell therapy FT596 ‘well tolerated’ in phase 1 trial

Cellular Therapy

CAR-NK cell therapy FT596 ‘well tolerated’ in phase 1 trial

Leukemia

CAR-NK cell therapy FT596 ‘well tolerated’ in phase 1 trial

Lymphoma

CAR-NK cell therapy FT596 ‘well tolerated’ in phase 1 trial

Multiple Myeloma

CAR-NK cell therapy FT596 ‘well tolerated’ in phase 1 trial

Myelodysplastic Syndromes

CAR-NK cell therapy FT596 ‘well tolerated’ in phase 1 trial

Myeloproliferative Neoplasms

Subscribe

Recent Posts

babis

What are the obstacles in utilization of golcadomide in DLBCL?

DOCK1 inhibition in TP53-mutant clonal hematopoiesis

European Commission

EC approves tafasitamab combo in relapsed follicular lymphoma

Copyright © 2025 Society of Hematologic Oncology, All rights reserved.